The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 131
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M., Boyle, G., Chang, L., Götz, J., Buisson, A., & Lesné, S. E. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 112
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 6×
“dence that AD is a transmissible prion-like disease [5], experimental data support the idea that A Os may spread from cell-to-cell and brain region-toregion in a prion-like manner.”
BackgroundInfluentialAmyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Items 401–500 of 867
Yanagisawa, D., Ibrahim, N. F., Taguchi, H., Morikawa, S., Tomiyama, T., & Tooyama, I. (2021) · Molecules · doi:10.3390/molecules26051362 · Cited by 13
Shear-induced amyloid formation of IDPs in the brain
Trumbore, C. N. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.008 · Cited by 14
Acetylation of Aβ 40 Alters Aggregation in the Presence and Absence of Lipid Membranes
Pilkington, A. W., Schupp, J. E., Nyman, M., Valentine, S. J., Smith, D. M., & Legleiter, J. A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00483 · Cited by 15
Ma, W., Chen, A.-F., Xie, X., & Huang, Y. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108342 · Cited by 13
β-Amyloid peptide interactions with biomimetic membranes: A multiparametric characterization
Smeralda, W., Since, M., Cardin, J., Corvaisier, S., Lecomte, S., Cullin, C., & Malzert‐Fréon, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.107 · Cited by 12
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 15
Kamei, N., Hashimoto, A., Tanaka, E., Murata, K., Yamaguchi, M., Yokoyama, N., Kato, M., Oki, K., Saito, T., Saido, T. C., et al. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01117-6 · Cited by 13
Souchet, B., Audrain, M., Gu, Y., Lindberg, M. F., Orefice, N. S., Rey, E., Cartier, N., Janel, N., Meijer, L., & Braudeau, J. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.18 · Cited by 13
A Disulfide-Stabilized Aβ that Forms Dimers but Does Not Form Fibrils
Zhang, S., Yoo, S., Snyder, D. T., Katz, B. B., Henrickson, A., Demeler, B., Wysocki, V. H., Kreutzer, A. G., & Nowick, J. S. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00739 · Cited by 17
Zhang, T., Song, C., Zheng, C., Chen, X., & Zhang, Y. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01219-2 · Cited by 13
A Multilevel Study of Eupatorin and Scutellarein as Anti-Amyloid Agents in Alzheimer’s Disease
Rizou, A. E. I., Nasi, G. I., Paikopoulos, Y., Bezantakou, D. S., Vraila, K. D., Spatharas, P. M., Dimaki, V. D., Papandreou, N. C., Lamari, F. N., Chondrogianni, N., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11051357 · Cited by 13
Zhang, Y., Zhang, J., Wang, Y., & Yao, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1234719 · Cited by 15
A Free Radical-Generating System Regulates Amyloid Oligomers: Involvement of Cathepsin B
Llorente, P., Kristen, H., Sastre, I., Toledano‐Zaragoza, A., Aldudo, J., Recuero, M., & Bullido, M. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170159 · Cited by 12
Ammassari‐Teule, M. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.566615 · Cited by 12
Mozzoni, K., Limegrover, C. S., Rehak, C., Yurko, R., Izzo, N. J., Knezovich, N., Watto, E., Waybright, L., & Catalano, S. M. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109180 · Cited by 12
S100B chaperone multimers suppress the formation of oligomers during Aβ42 aggregation
Figueira, A. J., Saavedra, J., Cardoso, I., & Gomes, C. M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1162741 · Cited by 12
Haerianardakani, S., Kreutzer, A. G., Salveson, P. J., Samdin, T. D., Guaglianone, G., & Nowick, J. S. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09281 · Cited by 12
The role of heat shock proteins in preventing amyloid toxicity
Törner, R., Kupreichyk, T., Hoyer, W., & Boisbouvier, J. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1045616 · Cited by 13
Li, X., She, L., Sun, J., Xu, X., Li, L., Zeng, Y., Tang, H., Liang, G., Wang, W., & Zhao, X. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00894 · Cited by 11
Arendash, G. W., Lin, X., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240600 · Cited by 13
Wärmländer, S. K. T. S., Lakela, A. L., Berntsson, E., Jarvet, J., & Gräslund, A. (2025) · ACS Omega · doi:10.1021/acsomega.4c05312 · Cited by 11
Singh, M. K., Fu, M., Han, S., Ranbhise, J. S., Choe, W., Kim, S. S., & Kang, I. (2025) · Cells · doi:10.3390/cells14151179 · Cited by 11
Zamponi, E., & Pigino, G. F. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00350 · Cited by 12
Membrane active Janus-oligomers of β 3 -peptides
Szigyártó, I. C., Mihály, J., Wacha, A., Bogdán, D., Juhász, T., Kohut, G., Schlosser, G., Zsila, F., Urlacher, V. B., Varga, Z., et al. (2020) · Chemical Science · doi:10.1039/d0sc01344g · Cited by 12
He, P., Schulz, P., & Sierks, M. R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015327 · Cited by 11
Martorana, A., Assogna, M., Lucia, V. D., Motta, C., Bonomi, C. G., Bernocchi, F., Donna, M. G. D., & Koch, G. (2021) · Minerva Medica · doi:10.23736/s0026-4806.21.07448-6 · Cited by 12
Schemmert, S., Camargo, L., Honold, D., Gering, I., Kutzsche, J., Willuweit, A., & Willbold, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126553 · Cited by 8
Hanaki, M., Murakami, K., Gunji, H., & Irie, K. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128613 · Cited by 12
Ex vivo analysis platforms for monitoring amyloid precursor protein cleavage
Kamikubo, Y., Jin, H., Zhou, Y., Niisato, K., Hashimoto, Y., Takasugi, N., & Sakurai, T. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1068990 · Cited by 13
Matrix Development for the Detection of Phosphorylated Amyloid-β Peptides by MALDI-TOF-MS
Liepold, T., Klafki, H., Kumar, S., Walter, J., Wirths, O., Wiltfang, J., & Jahn, O. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00270 · Cited by 13
Protein Self-Assembly at the Liquid–Surface Interface. Surface-Mediated Aggregation Catalysis
Lyubchenko, Y. L. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c09029 · Cited by 11
Influence of amyloid beta on impulse spiking of isolated hippocampal neurons
Yavorsky, V. A., Rozumna, N. M., & Lukyanetz, E. A. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1132092 · Cited by 11
Tan, R., Li, W., Pang, J.-M., Zhong, S.-M., Huang, X.-Y., Deng, J.-Z., Zhou, L., Wu, J., & Wang, X. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10651-5 · Cited by 12
Alzheimer’s Disease and Its Possible Evolutionary Origin: Hypothesis
Whitfield, J. F., Rennie, K., & Chakravarthy, B. (2023) · Cells · doi:10.3390/cells12121618 · Cited by 12
Contextualizing the Role of Osteopontin in the Inflammatory Responses of Alzheimer’s Disease
Lalwani, R. C., Volmar, C., Wahlestedt, C., Webster, K. A., & Shehadeh, L. A. (2023) · Biomedicines · doi:10.3390/biomedicines11123232 · Cited by 15
Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer’s Disease
Pyun, J., Kang, M. J., Ryoo, N., Suh, J., Youn, Y. C., Park, Y. H., & Kim, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200104 · Cited by 12
Yeates, C. J., Sarkar, A., Deshpande, P., Kango‐Singh, M., & Singh, A. (2020) · iScience · doi:10.1016/j.isci.2020.101823 · Cited by 11
Cross-Linked Amyloid β-Protein Oligomers: A Missing Link in Alzheimer’s Disease Pathology?
Urbanc, B. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c07716 · Cited by 13
The endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 23
Varinthra, P., Suresh, P., Chokkalingam, P., Ibiayo, A. G., & Liu, I. Y. (2022) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_139_22 · Cited by 12
A common pathway for detergent-assisted oligomerization of Aβ42
Muhammedkutty, F. N. K., Prasad, R., Gao, Y., Sudarshan, T. R., Robang, A. S., Watzlawik, J. O., Rosenberry, T. L., Paravastu, A. K., & Zhou, H. (2023) · Communications Biology · doi:10.1038/s42003-023-05556-w · Cited by 11
Yu, Z., Blade, G., Bouley, B. S., Dobrucki, I. T., Dobrucki, L. W., & Mirica, L. M. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.3c02929 · Cited by 11
Understanding Aβ Peptide Binding to Lipid Membranes: A Biophysical Perspective
Ahyayauch, H., Masserini, M., Alonso, A., & Goñi, F. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126401 · Cited by 10
Amyloid-β oligomer-induced neurotoxicity by exosomal interactions between neuron and microglia
Tong, M. K., Thakur, A., Yang, T., Wong, S. K., Li, W. K., & Lee, Y. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150312 · Cited by 11
Özdemir, A. Y., Çetin, E. A., Novotný, J., & Rudajev, V. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118157 · Cited by 12
Park, J. S., Choe, K., Ahmad, R., Park, H. Y., Kang, M. H., Park, T. J., & Kim, M. O. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.06.001 · Cited by 12
A human neuron Alzheimer’s disease model reveals barriers to senolytic translatability
Walton, C. C., Wang, E. Y., Lee, S., Siebrand, C. J., Bergo, N. J., Mayeri, Z., & Andersen, J. K. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01822-7 · Cited by 10
Wang, M., Zhang, L., Huang, W., Huang, J., Luo, Y., & Huang, N. (2025) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2025.103222 · Cited by 10
Targeting protein misfolding in Alzheimer’s disease: The emerging role of molecular chaperones
Sharma, A., Srivastava, S., Gupta, P., Sridhar, S. B., Tariq, M., Rao, G. K., Kumar, S., & Malik, T. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118531 · Cited by 15
Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease
Saito, Y., Sakata, M., Kobayakawa, M., Kawachi, H., Kawaguchi, K., Hiki, Y., Katô, M., Mori, M., Hasegawa, M., Ohashi, N., et al. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s241074 · Cited by 12
Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology
Laversenne, V., Nazeeruddin, S., Källstig, E., Colin, P., Voize, C., & Schneider, B. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01069-3 · Cited by 10
Wang, Y., Meng, F., Lu, T., Wang, C., & Li, F. (2021) · RSC Advances · doi:10.1039/d1ra00354b · Cited by 11
Wu, K. Y., Doan, D., Medrano, M. L. T., & Chang, C. A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1939163 · Cited by 13
Ko, C., Xu, J., Chang, Y.-W. W., Lo, Y.-M. M., Wu, J. S., Huang, W., & Shen, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.788723 · Cited by 10
Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease
Tyler, S. E. B., & Tyler, L. D. K. (2022) · Natural Products and Bioprospecting · doi:10.1007/s13659-022-00354-z · Cited by 10
Nath, A. K., Roy, M., Dey, C., Dey, A., & Dey, S. G. (2022) · Chemical Science · doi:10.1039/d2sc05008k · Cited by 11
Ihsan, N. S. M. N., Sani, S. F. A., Looi, L., Cheah, P., Chiew, S.-F., Pathmanathan, D., & Bradley, D. A. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.06.002 · Cited by 10
Thwe, P. N., Yeong, K. Y., & Choo, W. S. (2023) · Plant Foods for Human Nutrition · doi:10.1007/s11130-023-01081-7 · Cited by 11
Arrigoni, F., Rizza, F., Tisi, R., GIOIA, L. D., Zampella, G., & Bertini, L. (2020) · Metallomics · doi:10.1039/d0mt00113a · Cited by 12
Ionic Environment Affects Biomolecular Interactions of Amyloid-β: SPR Biosensor Study
Hemmerová, E., Špringer, T., Krištofiková, Z., & Homola, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249727 · Cited by 10
Wickstead, E. S., Irving, M. A., Getting, S. J., & McArthur, S. (2021) · FEBS Journal · doi:10.1111/febs.15861 · Cited by 11
Hwang, D.-J., Choi, D.-H., Kwon, K.-C., Kim, E., Kim, T., Koo, J., & Cho, J. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002834 · Cited by 10
Merlo, S., Caruso, G. I., Bonfili, L., Spampinato, S. F., Costantino, G., Eleuteri, A. M., & Sortino, M. A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115151 · Cited by 12
Önder, S., Biberoğlu, K., Tacal, Ö., & Schopfer, L. M. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110029 · Cited by 10
Schechter, G., Azad, G. K., Rao, R. V., McKeany, A. M., Matulaitis, M., Kalos, D. M., & Kennedy, B. K. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200185 · Cited by 10
Prasad, A. K., Samajdar, R., Panwar, A. S., & Martin, L. L. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c02594 · Cited by 9
Kengwerere, M. K., Kenyaga, J. M., Xiao, P., Gunaga, S. S., Scott, F. J., Wutoh-Hughes, X., Wang, J., Lum, B., Sun, Y. P., Mentink‐Vigier, F., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01537-8 · Cited by 9
Targeting mitochondrial dysfunction in Alzheimer's disease: New findings and perspectives
Hroudová, J., & Fišar, Z. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111491 · Cited by 11
Origin, toxicity and characteristics of two amyloid oligomer polymorphs
Niyangoda, C., Barton, J., Bushra, N., Karunarathne, K., Strauss, G. L., Fakhre, F., Koria, P., & Muschol, M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00081k · Cited by 10
Miao, Y., Tang, X. L., & Han, W. (2022) · Chemical Science · doi:10.1039/d1sc06337e · Cited by 9
Chen, C., Jong, Y., Chao, Y.-Y., Wang, C., & Chen, Y. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04350-7 · Cited by 10
Murakami, K., Sakaguchi, Y., Taniwa, K., Izuo, N., Hanaki, M., Kawase, T., Hirose, K., Shimizu, T., & Irie, K. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00194b · Cited by 9
Allnutt, M. A., & Matera, K. M. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04036-1 · Cited by 10
EPR Studies of Aβ42 Oligomers Indicate a Parallel In-Register β-Sheet Structure
Jang, C., Barron, D. P., Duo, L., Ma, C., Seabaugh, H., & Guo, Z. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00364 · Cited by 9
Exploring the mechanisms of chrysin in combating Alzheimer's disease: therapeutic perspectives
Singh, T. G., SHARMA, A. K., & Devi, S. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.162341 · Cited by 10
Ikeda, K., Sugiura, Y., Nakao, H., & Nakano, M. (2024) · Biophysical Chemistry · doi:10.1016/j.bpc.2024.107248 · Cited by 9
Development of Triphenylmethane Dyes for In Vivo Fluorescence Imaging of Aβ Oligomers
Nagashima, K., Watanabe, H., Akasaka, T., & Ono, M. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00053 · Cited by 11
Alzheimer’s Disease Neuropathological Change in Aged Non-Primate Mammals
Ferrer, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158118 · Cited by 15
Peng, X., Gibbs, E., Silverman, J. M., Cashman, N. R., & Plotkin, S. S. (2021) · Statistical Methods in Medical Research · doi:10.1177/09622802211002861 · Cited by 11
Mechanism of Cellular Formation and In Vivo Seeding Effects of Hexameric β-Amyloid Assemblies
Vrancx, C., Vadukul, D. M., Suelves, N., Contino, S., D’Auria, L., Perrin, F., Pesch, V. V., Hanseeuw, B. J., Quinton, L., & Kienlen‐Campard, P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02567-8 · Cited by 9
Signaling interactions among neurons impact cell fitness and death in Alzheimer’s disease
Yeates, C. J., Deshpande, P., Kango-Singh, M., & Kango‐Singh, M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.354516 · Cited by 9
SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β–induced synaptic pathology
Lee, A. K., Yi, N., Khaled, H., Feller, B., Chofflet, N., & Takahashi, H. (2023) · Life Science Alliance · doi:10.26508/lsa.202201681 · Cited by 11
Degradation of amyloid β-peptides catalyzed by nattokinase in vivo and in vitro
Ni, A., Li, H., Wang, R., Sun, R., & Zhang, Y. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.02.042 · Cited by 9
Introducing Virtual Oligomerization Inhibition to Identify Potent Inhibitors of Aβ Oligomerization
Man, V. H., He, X., Ji, B., Liu, S., Xie, X., & Wang, J. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.0c00185 · Cited by 9
Pensalfini, A., Umar, A. R., Glabe, C. G., Parker, I., Ullah, G., & Demuro, A. (2022) · Cells · doi:10.3390/cells11223630 · Cited by 9
Hammers, D. B., Musema, J., Eloyan, A., Thangarajah, M., Taurone, A., Joie, R. L., Touroutoglou, A., Vemuri, P., Kramer, J. H., Aisen, P., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100075 · Cited by 8
Randhawa, S., Saini, T. C., Bathla, M., Bhardwaj, R., Dhiman, R., & Acharya, A. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.44 · Cited by 9
Oral diseases as emerging risk factors for Alzheimer’s disease: A scoping review
Yi, Y., Lee, C., Shin, H., & Shin, S. (2025) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2025.11.003 · Cited by 9
Victorino, D. B., Faber, J., Pinheiro, D. J. L. L., Scorza, F. A., de Almeida, A.-C. G., Costa, A. C. S., & Scorza, C. A. (2022) · Aging and Disease · doi:10.14336/ad.2022.0906 · Cited by 11
Mechanistic insights into the inhibition of amyloid-β aggregation by chitosan
Gotla, S., & Matysiak, S. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp00162h · Cited by 10
McCalpin, S. D., Widanage, M. C. D., Fu, R., & Ramamoorthy, A. (2023) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.3c02009 · Cited by 8
Беличенко, В. М., Bashirzade, A. A., Tenditnik, M. V., Dubrovina, N. I., Akopyan, A. A., Ovsyukova, M. V., Fedoseeva, L. A., Pupyshev, A. B., Aftanas, L. I., Amstislavskaya, T. G., et al. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114651 · Cited by 9
Marshall, K. E., Mengham, K., Spink, M. C., Vania, L., Pollard, H. J., Darrow, M. C., Duke, E., Harkiolaki, M., & Serpell, L. C. (2024) · Structure · doi:10.1016/j.str.2024.02.010 · Cited by 10
Strategies for measuring concentrations and forms of amyloid-β peptides
Shen, H., Liu, K., Kong, F., Ren, M., Wang, X., & Wang, S. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116405 · Cited by 10
Liu, J., Chen, L., Zhang, Z., Wen, W., Zhang, X., Wu, Z., & Wang, S. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c04598 · Cited by 8
Melatonin Supplementation in Alzheimer’s disease: The Potential Role in Neurogenesis
Ebrahimi, R., Faramarzi, A., Salarvandian, S., Zarei, R., Heidari, M., Salehian, F., & Esmaeilpour, K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05095-x · Cited by 8
Saha, D., & Jana, B. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp01866c · Cited by 8
Additions to Alpha-Sheet Based Hypotheses for the Cause of Alzheimer’s Disease
Serwer, P., Wright, E. T., & Hunter, B. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220311 · Cited by 8
Trumbore, C. N., & Raghunandan, A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220622 · Cited by 8
Maintenance of Amyloid-beta Homeostasis by Carbenoxolone Post Aβ-42 Oligomer Injection in Rat Brain
Sharma, S., Saini, R., Sharma, P., Saini, A., & Nehru, B. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.004 · Cited by 8
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.